| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | GAL5 |
| Uniprot No | P37012 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-569aa |
| 氨基酸序列 | MSFQIETVPTKPYEDQKPGTSGLRKKTKVFKDEPNYTENFIQSIMEAIPEGSKGATLVVGGDGRYYNDVILHKIAAIGAANGIKKLVIGQHGLLSTPAASHIMRTYEEKCTGGIILTASHNPGGPENDMGIKYNLSNGGPAPESVTNAIWEISKKLTSYKIIKDFPELDLGTIGKNKKYGPLLVDIIDITKDYVNFLKEIFDFDLIKKFIDNQRSTKNWKLLFDSMNGVTGPYGKAIFVDEFGLPADEVLQNWHPSPDFGGMHPDPNLTYASSLVKRVDREKIEFGAASDGDGDRNMIYGYGPSFVSPGDSVAIIAEYAAEIPYFAKQGIYGLARSFPTSGAIDRVAKAHGLNCYEVPTGWKFFCALFDAKKLSICGEESFGTGSNHVREKDGVWAIMAWLNILAIYNKHHPENEASIKTIQNEFWAKYGRTFFTRYDFEKVETEKANKIVDQLRAYVTKSGVVNSAFPADESLKVTDCGDFSYTDLDGSVSDHQGLYVKLSNGARFVLRLSGTGSSGATIRLYIEKYCDDKSQYQKTAEEYLKPIINSVIKFLNFKQVLGTEEPTVRT |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GAL5重组蛋白的3篇假设性参考文献示例(仅供格式参考，实际文献需根据具体研究查询)：
---
1. **标题**：*Optimization of Recombinant GAL5 Expression in E. coli for Enzymatic Studies*
**作者**：Chen L, et al.
**摘要**：研究通过密码子优化和诱导条件调控，在大肠杆菌中高效表达可溶性GAL5重组蛋白，并验证其半乳糖苷酶活性。
2. **标题**：*Structural Characterization of GAL5 Protein Using Cryo-EM*
**作者**：Wang Y, et al.
**摘要**：利用冷冻电镜解析GAL5重组蛋白的三维结构，揭示其底物结合域和催化机制，为酶工程改造提供依据。
3. **标题**：*Functional Analysis of GAL5 in Plant Cell Wall Biosynthesis*
**作者**：Smith J, et al.
**摘要**：通过重组GAL5蛋白体外实验，证明其参与植物细胞壁多糖合成通路，并探讨其与底物特异性相关的关键氨基酸残基。
---
实际研究中，建议通过 **PubMed** 或 **Web of Science** 搜索关键词 "GAL5 recombinant protein" 获取真实文献。若研究较少，可尝试扩展关键词(如相关家族蛋白或功能描述)。
The GAL5 recombinant protein is a genetically engineered protein derived from the GAL4 transcription activator system, originally identified in the yeast *Saccharomyces cerevisiae*. GAL4 regulates galactose metabolism by binding upstream activating sequences (UAS) of target genes. The recombinant GAL5 variant, while less commonly referenced than GAL4. is hypothesized to function similarly, serving as a customizable molecular tool for gene expression control in synthetic biology and genetic research. It typically retains the modular structure of GAL4. comprising a DNA-binding domain (DBD) for sequence-specific targeting and an activation domain (AD) to recruit transcriptional machinery.
Recombinant GAL5 is often engineered to enhance specificity, reduce off-target effects, or integrate fusion partners for optogenetic, chemical-inducible, or cell-specific regulation. Its applications span yeast-based systems, mammalian cell cultures, and transgenic organisms, enabling precise gene activation in studies of gene networks, signaling pathways, or therapeutic protein production. For example, GAL5-based systems are employed in two-hybrid assays to map protein interactions or inducible gene therapies to control therapeutic transgenes.
Production typically involves expression in *E. coli* or yeast, followed by purification via affinity tags (e.g., His-tag). Challenges include optimizing DNA-binding specificity and minimizing cross-reactivity with endogenous systems. Recent advancements in CRISPR/dCas9 systems have partially supplanted traditional GAL-based tools, but GAL5 retains utility in contexts requiring high-level, tunable expression without genome editing. Ongoing research explores hybrid systems combining GAL5-derived DBDs with epigenetic modifiers or synthetic co-activators to expand its versatility in synthetic biology and biomanufacturing.
×
